Exogenous C-type natriuretic peptide infusion ameliorates unilateral ureteral obstruction-induced tubulointerstitial fibrosis in rats

Laboratory Investigation

Volumn 95, Issue 3, 2015, Pages 263-272

  Hu, Peng ^a   Zhang, Xiao Cen ^a,b   Kong, Hai Bo ^a   Xia, Xun ^a   Hu, Bo ^a   Qin, Yuan Han ^c  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b People's Hospital of Fuyang   (China)

^c FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; GELATINASE A; GELATINASE B; NATRIURETIC PEPTIDE TYPE C; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOWN REGULATION; INFUSION; KIDNEY PARENCHYMA; LABORATORY TEST; MALE; NONHUMAN; OBSTRUCTION-INDUCED RENAL FIBROSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RADIOIMMUNOASSAY; RAT; REAL TIME POLYMERASE CHAIN REACTION; SHAM PROCEDURE; TUBULOINTERSTITIAL FIBROSIS; URETER OBSTRUCTION; URINALYSIS; ANIMAL; BLOOD; COMPLICATION; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASES; KIDNEY TUBULE; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; BLOTTING, WESTERN; COLLAGEN TYPE IV; FIBROSIS; GENE EXPRESSION; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; KIDNEY TUBULES; MALE; MATRIX METALLOPROTEINASE 9; NATRIURETIC PEPTIDE, C-TYPE; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; URETERAL OBSTRUCTION;

EID: 84928601145     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.149     Document Type: Article

References (49)

1. Stryjewski PJ, Nessler B, Cubera K, et al. Natriuretic peptides. History of discovery, chemical structure, mechanism of action and the removal routes. Basis of diagnostic and therapeutic use. Przegl Lek 2013;70:463-467.
2. Sudoh T, Minamino N, Kangawa K, et al. C-type natriuretic peptide (CNP): a new member of the natriuretic peptide family identified in porcine brain. Biochem Biophys Res Comm 1990;168:863-870.
3. Leuranguer V, Vanhoutte PM, Verbeuren T, et al. C-type natriuretic peptide and endothelium-dependent hyperpolarization in the guineapig carotid artery. Br J Pharmacol 2008;153:57-65.
4. Del Ry S, Cabiati M, Vozzi F, et al. Expression of C-type natriuretic peptide and its receptor NPR-B in cardiomyocytes. Peptides 2011;32: 1713-1718.
5. Suda M, Tanaka K, Fukushima M, et al. C-type natriuretic peptide as an autocrine/paracrine regulator of osteoblast. Evidence for possible presence of bone natriuretic peptide system. Biochem Biophys Res Commun 1996;223:1-6.
6. Totsune K, Takahashi K, Murakami O, et al. Immunoreactive C-type natriuretic peptide in human adrenal glands and adrenal tumors. Peptides 1994;15:287-290.
7. Nielsen SJ, Gøtze JP, Jensen HL, et al. ProCNP and CNP are expressed primarily in male genital organs. Regul Pept 2008;146:204-212.
8. Kalra PR, Clague JR, Coats AJ, et al. C-type natriuretic peptide production by the human kidney is blunted in chronic heart failure. Clin Sci (Lond) 2009;118:71-77.
9. Prickett TC1 Charles CJ, Yandle TG, et al. Skeletal contributions to plasma CNP forms: evidence from regional sampling in growing lambs. Peptides 2009;30:2343-2347.
10. Hu P, Wang J, Zhao XQ, et al. Overexpressed C-type natriuretic peptide serves as an early compensatory response to counteract extracellular matrix remodeling in unilateral ureteral obstruction rats. Mol Biol Rep 2013;40:1429-1441.
11. Hu P, Zhao XQ, Wang J, et al. Paradoxical expressions of natriuretic peptide receptor-C and neutral endopeptidase account for C-type natriuretic peptide decline during the progression of experimental obstructive nephropathy. J Renin Angiotensin Aldosterone Syst; advance online publication, 4 November 2013 (e-pub ahead of print).
12. Hu P, Wang J, Hu B, et al. Increased urinary C-type natriuretic peptide excretion may be an early marker of renal tubulointerstitial fibrosis. Peptides 2012;37:98-105.
13. Villar IC, Panayiotou CM, Sheraz A, et al. Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor. Cardiovasc Res 2007;74:515-525.
14. Komatsu Y, Itoh H, Suga S, et al. Regulation of endothelial production of C-type natriuretic peptide in coculture with vascular smooth muscle cells. Role of the vascular natriuretic peptide system in vascular growth inhibition. Circ Res 1996;78:606-614.
15. Doi K, Ikeda T, Itoh H, et al. C-type natriuretic peptide induces redifferentiation of vascular smooth muscle cells with accelerated reendothelialization. Arterioscler Thromb Vasc Biol 2001;21:930-936.
16. Hayashi MA, Murbach AF, Ianzer D, et al. The C-type natriuretic peptide precursor of snake brain contains highly specific inhibitors of the angiotensin-converting enzyme. J Neurochem 2003;85:969-977.
17. Izumiya Y, Araki S, Usuku H, et al. Chronic C-type natriuretic peptide infusion attenuates angiotensin II-induced myocardial superoxide production and cardiac remodeling. Int J Vasc Med 2012;2012:246058.
18. Itoh T, Nagaya N, Murakami S, et al. C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;170:1204-1211.
19. Del Ry S, Maltinti M, Emdin M, et al. Radioimmunoassay for plasma C-type natriuretic peptide determination: a methodological evaluation. Clin Chem Lab Med 2005;43:641-645.
20. Hu P, Zhao XQ, Wang J, et al. Simplified stereological evaluation of renal morphology after unilateral ureteral obstruction. Int J Med Sci 2013;10:385-391.
21. Bae EH, Kim SW. Upregulation of renin-angioteinsin, endothelin and C-type natriuretic peptide in rat glomerulus with bilateral ureteral obstruction. Korean J Physiol Pharmacol 2006;10:343-348.
22. Garvey SM, Sinden DS, Schoppee Bortz PD, et al. Cyclosporine upregulates Krüppel-like factor-4 (KLF4) in vascular smooth muscle cells and drives phenotypic modulation in vivo. J Pharmacol Exp Ther 2010;333:34-42.
23. Qin YH, Lei FY, Hu P, et al. Effect of all-trans retinoic acid on renal expressions of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rats with glomerulosclerosis. Pediatr Nephrol 2009;24:1477-1486.
24. Schäfer S, Ellinghaus P, Janssen W, et al. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res 2009;82:30-39.
25. Bowman CJ, Turner KJ, Sar M, et al. Altered gene expression during rat Wolffian duct development following di(n-butyl) phthalate exposure. Toxicol Sci 2005;86:161-174.
26. Nagai Y, Yao L, Kobori H, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005;16:703-711.
27. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-1108.
28. Farris AB, Colvin RB. Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens 2012;21:289-300.
29. Satoh M. Endothelial dysfunction as an underlying pathophysiological condition of chronic kidney disease. Clin Exp Nephrol 2012;16:518-521.
30. Liang CF, Au AL, Leung SW, et al. Endothelium-derived nitric oxide inhibits the relaxation of the porcine coronary artery to natriuretic peptides by desensitizing big conductance calcium-activated potassium channels of vascular smooth muscle. J Pharmacol Exp Ther 2010;334:223-231.
31. Zhou TB, Qin YH, Lei FY, et al. Association of prohibitin-1 and 2 with oxidative stress in rats with renal interstitial fibrosis. Mol Biol Rep 2014;41:3033-3043.
32. Hu P, Lu L, Hu B, et al. Renal action of C-type natriuretic peptide: advocating the isolated perfused rat kidney model. Saudi J Kidney Dis Transpl 2010;21:613-620.
33. La Villa G, Mannelli M, Lazzeri C, et al. Different effects of atrial and C-type natriuretic peptide on the urinary excretion of endothelin-1 in man. Clin Sci (Lond) 1998;95:595-602.
34. Barletta G, Lazzeri C, Vecchiarino S, et al. Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans. Hypertension 1998;31:802-808.
35. Pham I, Sediame S, Maistre G, et al. Renal and vascular effects of C-type and atrial natriuretic peptides in humans. Am J Physiol 1997;273:R1457-R1464.
36. Brunner F, Wölkart G. Relaxant effect of C-type natriuretic peptide involves endothelium and nitric oxide-cGMP system in rat coronary microvasculature. Cardiovasc Res 2001;51:577-584.
37. Chauhan SD, Nilsson H, Ahluwalia A, et al. Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci USA 2003;100:1426-1431.
38. Honing ML, Smits P, Morrison PJ, et al. C-type natriuretic peptideinduced vasodilation is dependent on hyperpolarization in human forearm resistance vessels. Hypertension 2001;37:1179-1183.
39. Davidson NC, Barr CS, Struthers AD. C-type natriuretic peptide. An endogenous inhibitor of vascular angiotensin-converting enzyme activity. Circulation 1996;93:1155-1159.
40. Zhou TB, Qin YH, Lei FY, et al. Prohibitin attenuates oxidative stress and extracellular matrix accumulation in renal interstitial fibrosis disease. PLoS One 2013;8:e77187.
41. Gonzalez J, Mouttalib S, Delage C, et al. Dual effect of chemokine CCL7/MCP-3 in the development of renal tubulointerstitial fibrosis. Biochem Biophys Res Commun 2013;438:257-263.
42. Kawada N, Moriyama T, Ando A, et al. Increased oxidative stress in mouse kidneys with unilateral ureteral obstruction. Kidney Int 1999;56:1004-1013.
43. Canaan-Kühl S, Ostendorf T, Zander K, et al. C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo. Kidney Int 1998;53:1143-1151.
44. Osawa H, Yamabe H, Kaizuka M, et al. C-Type natriuretic peptide inhibits proliferation and monocyte chemoattractant protein-1 secretion in cultured human mesangial cells. Nephron 2000;86:467-472.
45. Lelongt B, Trugnan G, Murphy G, et al. Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro. J Cell Biol 1997;136:1363-1373.
46. Sekiuchi M, Kudo A, Nakabayashi K, et al. Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of matrix metalloproteinases 2 and 1 in the glomeruli of human glomerular diseases: the results of studies using immunofluorescence, in situ hybridization, and immunoelectron microscopy. Clin Exp Nephrol 2012;16:863-874.
47. Hu P, Qin YH, Pei J, et al. Beneficial effect of all-trans retinoic acid (ATRA) on glomerulosclerosis rats via the down-regulation of the expression of alpha-smooth muscle actin: a comparative study between ATRA and benazepril. Exp Mol Pathol 2010;89:51-57.
48. Hu P, Xuan Q, Hu B, et al. Anti-neutral endopeptidase, natriuretic peptides disarrangement, and proteinuria onset in membranous nephropathy. Mol Biol Rep 2013;40:2963-2967.
49. Qin YH, Zhou TB, Lei FY, et al. Cut-off values for serum matrix metalloproteinase-9: is there a threshold to predict renal involvement for Henoch-Schonlein purpura in children? Nephrology (Carlton) 2011;16:93-99.